Faricimab
- Generic Name
- Faricimab
- Brand Names
- Vabysmo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1607793-29-2
- Unique Ingredient Identifier
- QC4F7FKK7I
- Background
Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization (NV). Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies such as...
- Indication
Faricimab is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).
- Associated Conditions
- Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD), Visual Impairment
- Associated Therapies
- -
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 5000
- Registration Number
- NCT05476926
- Locations
- 🇨🇱
Centro de la Vision, Las Condes, Chile
🇩🇪Universitaetsklinikum Jena, Jena, Germany
🇩🇪Universitaetsklinikum Koeln, Koeln, Germany
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 218
- Registration Number
- NCT05224102
- Locations
- 🇺🇸
NJ Retina - Teaneck, Teaneck, New Jersey, United States
🇺🇸Barnet Dulaney Perkins Eye Center, Mesa, Arizona, United States
🇺🇸Win Retina, Arcadia, California, United States
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1036
- Registration Number
- NCT04777201
- Locations
- 🇺🇸
Barnet Dulaney Perkins Eye Center, Mesa, Arizona, United States
🇺🇸Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States
🇺🇸Associated Retina Consultants, Phoenix, Arizona, United States
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
- Conditions
- Interventions
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 553
- Registration Number
- NCT04740905
- Locations
- 🇵🇱
Gabinet Okulistyczny Prof Edward Wylegala, Katowice, Poland
🇺🇸Cumberland Valley Retina PC, Hagerstown, Maryland, United States
🇦🇺The Lions Eye Institute, Nedlands, Western Australia, Australia
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion
- Conditions
- Interventions
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 729
- Registration Number
- NCT04740931
- Locations
- 🇺🇸
Fort Lauderdale Eye Institute, Plantation, Florida, United States
🇺🇸Assoc Retinal Consultants PC, Royal Oak, Michigan, United States
🇺🇸Midwest Vision Research Foundation, Chesterfield, Missouri, United States
A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 99
- Registration Number
- NCT04597918
- Locations
- 🇺🇸
Austin Research Center for Retina, Austin, Texas, United States
🇩🇪Universitätsklinikum Tübingen, Tübingen, Germany
🇮🇹Ospedale San Giuseppe; U.O. Oculistica, Milano, Lombardia, Italy
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1479
- Registration Number
- NCT04432831
- Locations
- 🇺🇸
Barnet Dulaney Perkins Eye Center, Mesa, Arizona, United States
🇺🇸Retinal Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
- Conditions
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 671
- Registration Number
- NCT03823287
- Locations
- 🇵🇱
Dobry Wzrok Sp Z O O, Gdańsk, Poland
🇵🇱Gabinet Okulistyczny Prof Edward Wylegala, Katowice, Poland
🇵🇱SPEKTRUM Osrodek Okulistyki Klinicznej, Wroclaw, Poland
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
- Conditions
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 658
- Registration Number
- NCT03823300
- Locations
- 🇦🇷
Centro Oftalmológico Dr. Charles S.A., Capital Federal, Argentina
🇵🇹Hospital de Sao Joao; Servico de Oftalmologia, Porto, Portugal
🇺🇸The Retina Care Center, Baltimore, Maryland, United States
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
- Conditions
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 940
- Registration Number
- NCT03622580
- Locations
- 🇺🇸
Orange County Retina Med Group, Santa Ana, California, United States
🇺🇸Kaiser Permanente Riverside Medical Center, Riverside, California, United States
🇺🇸Cumberland Valley Retina PC, Hagerstown, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.